

# Charles L Shapiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5997585/publications.pdf>

Version: 2024-02-01

59  
papers

4,164  
citations

257450

24  
h-index

182427

51  
g-index

61  
all docs

61  
docs citations

61  
times ranked

6463  
citing authors

#	ARTICLE	IF	CITATIONS
1	Side Effects of Adjuvant Treatment of Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 1997-2008.	27.0	596
2	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-311.	1.6	521
3	Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 3306-3311.	1.6	417
4	Cancer Survivorship. <i>New England Journal of Medicine</i> , 2018, 379, 2438-2450.	27.0	382
5	Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 48.	7.4	253
6	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2270-2290.	1.6	224
7	NCCN Task Force Report: Bone Health in Cancer Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, S-1-S-32.	4.9	163
8	Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?. <i>Lancet Oncology</i> , The, 2017, 18, e445-e456.	10.7	135
9	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 2916-2946.	1.6	127
10	Osteopenia and osteoporosis in women with breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 763-775.	2.2	125
11	Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2541-2541.	1.6	124
12	Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement. <i>Journal of Oncology Practice</i> , 2016, 12, e828-e838.	2.5	102
13	Bone Health in Adult Cancer Survivorship. <i>Journal of Clinical Oncology</i> , 2012, 30, 3665-3674.	1.6	101
14	Androgen Receptor Status Is a Prognostic Marker in Non-Basal Triple Negative Breast Cancers and Determines Novel Therapeutic Options. <i>PLoS ONE</i> , 2014, 9, e88525.	2.5	79
15	Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 2311-2317.	1.6	70
16	The quality of care for treatment of early stage breast carcinoma. , 1998, 83, 302-309.		69
17	ReCAP: ASCO Core Curriculum for Cancer Survivorship Education. <i>Journal of Oncology Practice</i> , 2016, 12, 145-145.	2.5	61
18	Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3949-3955.	1.6	57

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. <i>Cancer</i> , 2001, 91, 17-24.	4.1	44
20	Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials. <i>Oncologist</i> , 2015, 20, 337-343.	3.7	43
21	Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. <i>Oncotarget</i> , 2015, 6, 6373-6385.	1.8	42
22	Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating $\beta$ -Secretase-Mediated Notch1 Activation in Caveolae. <i>Neoplasia</i> , 2015, 17, 497-508.	5.3	38
23	Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 495-501.	2.5	34
24	Assuring Quality Cancer Survivorship Care: We've Only Just Begun. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e583-e591.	3.8	31
25	Clinical and Pathologic Features of Breast Cancers in Women Treated for Hodgkin's Disease: A Case-Control Study. <i>Breast Journal</i> , 2001, 7, 46-52.	1.0	30
26	Chronic comorbid conditions among adult cancer survivors in the United States: Results from the National Health Interview Survey, 2002-2018. <i>Cancer</i> , 2022, 128, 828-838.	4.1	27
27	Self-reported Transportation Barriers to Health Care Among US Cancer Survivors. <i>JAMA Oncology</i> , 2022, 8, 775.	7.1	25
28	Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments. <i>Cancers</i> , 2020, 12, 3094.	3.7	24
29	Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. <i>Cancer</i> , 1991, 68, 699-705.	4.1	23
30	Aromatase Inhibitor-Associated Bone Loss. <i>Drugs</i> , 2008, 68, 2591-2600.	10.9	22
31	Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008777.	2.6	22
32	Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors. <i>JAMA Oncology</i> , 2016, 2, 1401.	7.1	21
33	Osteoporosis and musculoskeletal complications related to therapy of breast cancer. <i>Gland Surgery</i> , 2018, 7, 411-423.	1.1	19
34	Integrin-linked kinase as a novel molecular switch of the IL-6-NF- $\kappa$ B signaling loop in breast cancer. <i>Carcinogenesis</i> , 2016, 37, 430-442.	2.8	18
35	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
36	CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9501-9501.	1.6	16

#	ARTICLE	IF	CITATIONS
37	Treatment-Related Mortality With Everolimus in Cancer Patients. <i>Oncologist</i> , 2014, 19, 661-668.	3.7	12
38	Bone-modifying Agents (BMAs) in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e618-e630.	2.4	9
39	Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience. <i>Supportive Care in Cancer</i> , 2018, 26, 197-202.	2.2	8
40	Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2019, 15, 603-606.	2.5	4
41	Management of osteoporosis in women with breast cancer. <i>Breast Cancer Management</i> , 2020, 9, .	0.2	4
42	Real-world clinical outcomes in patients with local/regional HER2-low breast cancer: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 558-558.	1.6	4
43	De-escalation yes, but not at the expense of efficacy: in defense of better treatment. <i>Npj Breast Cancer</i> , 2019, 5, 25.	5.2	3
44	Quality Care in Survivorship: Lessons Learned From the ASCO Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2021, 17, e1170-e1180.	2.9	3
45	A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3116-TPS3116.	1.6	3
46	Cancer survivors with multiple chronic conditions: A rising challenge—Trend analysis from National Health Interview Survey.. <i>Journal of Clinical Oncology</i> , 2020, 38, e24089-e24089.	1.6	3
47	Survival of patients with lung cancer treated with vincristine and actinomycin D.An unsuccessful trial. <i>Cancer</i> , 1976, 37, 1669-1672.	4.1	2
48	Zoledronic Acid Dosing Interval for Metastatic Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1478.	7.4	2
49	Reply to L. Kennedy et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 1052-1053.	1.6	2
50	The quality of care for treatment of early stage breast carcinoma. <i>Cancer</i> , 1998, 83, 302-309.	4.1	2
51	Comparison of weight loss among early stage breast cancer patients post treatment: Nutrition education in combination with weight loss acupuncture vs. nutrition education alone.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12594-e12594.	1.6	1
52	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1103-TPS1103.	1.6	1
53	Central nervous system metastases in triple-negative breast cancer: A step in the right direction. <i>Breast Journal</i> , 2019, 25, 361-362.	1.0	0
54	Digitizing the cancer care continuum: Electronic, shareable survivorship care plans.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10101-10101.	1.6	0

#	ARTICLE	IF	CITATIONS
55	A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS1109-TPS1109.	1.6	0
56	Gender disparity on cigarette smoking among cancer survivors: Results from the National Health Interview Survey.. Journal of Clinical Oncology, 2020, 38, e24040-e24040.	1.6	0
57	Results of a phase Ib study investigating durvalumab in combination with eribulin in patients with metastatic HER2-negative breast cancer and recurrent ovarian cancer.. Journal of Clinical Oncology, 2020, 38, e15120-e15120.	1.6	0
58	Abstract PO-140: Unsupervised clustering and data modeling reveals molecular signatures linked a distinct African American enriched cluster with higher probability of death in triple negative breast cancer. , 2022, , .		0
59	Self-reported well-being of cancer survivor (CS)-caregivers: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS).. Journal of Clinical Oncology, 2022, 40, e22022-e22022.	1.6	0